Real-World Monitoring Costs Associated with Initiation of Disease-Modifying Therapy Among Patients with Multiple Sclerosis (P3.401)

Conclusions:Results from this study using real-world claims data indicate significant differences in monitoring costs associated with DMT initiation, with costs generally lowest for GA and highest for NAT. Lower monitoring costs should improve the overall cost–benefit profile of GA compared with other DMTs.Disclosure: Dr. Lage received research support from Teva Pharmaceuticals. Dr. Wu has received personal compensation for activities with Teva Neuroscience as an employee.
Source: Neurology - Category: Neurology Authors: Tags: Economic Implications of Multiple Sclerosis Source Type: research